Rxsight Inc (RXST) Q4 2025 Earnings Call Transcript

Why It Matters

The shift toward higher‑margin LAL sales improves profitability while the revenue contraction and margin pressure signal execution risks, making RxSight’s cash cushion and clinical advantage critical for investors and the premium intraocular lens market.

Key Takeaways

• Q4 sales $32.6M, down 19% YoY
• LALs represent 86% of revenue, boosting margin
• Full‑year cash $228M, no debt
• 2026 revenue guidance $120‑135M, ~5% decline
• Study shows 93% eyes within half‑diopter target

Pulse Analysis

RxSight’s business model hinges on two complementary technologies: the Light Delivery Device (LDD) that activates post‑operative adjustments, and the Light Adjustable Lens (LAL) that delivers the final refractive outcome. In 2025 the company’s product mix pivoted dramatically toward the LAL, which now generates 86% of quarterly revenue. This higher‑margin mix drove gross margins up to 77.5% in the fourth quarter, offsetting the steep decline in LDD placements that cut total sales by nearly one‑fifth. The transition underscores a broader industry trend where premium intraocular lenses command stronger pricing power and better profitability than the ancillary hardware that supports them.

Financially, RxSight entered 2026 with a robust balance sheet—$228 million in cash and no debt—providing a buffer against the anticipated 5% revenue dip and a modest margin contraction to 70‑72% due to higher‑cost inventory sell‑through. Operating expenses are expected to hover between $150 million and $160 million, reflecting a disciplined approach to U.S. commercial expansion while laying the groundwork for measured international rollout. The company’s guidance signals cautious optimism: sequential improvement is projected after a soft first quarter, and the modest expense growth suggests management is prioritizing cash efficiency over aggressive scaling.

The clinical narrative adds a compelling layer to the investment thesis. A newly published study showed 93% of LAL‑treated eyes achieved spherical equivalent and residual cylinder within half a diopter of target, outperforming conventional toric lenses. This evidence bolsters the LAL’s value proposition in the premium IOL segment, where surgeons and patients increasingly demand precise, spectacle‑independent outcomes. As myopia prevalence rises and cataract surgery moves earlier in patients’ lives, the demand for adjustable, high‑accuracy lenses is likely to accelerate, positioning RxSight to capture a growing share of a lucrative, technology‑driven market.